Myeloid cell reprogramming in aortic valve stenosis

Recruiting

• Conditions: Aortic valve stenosis; cardiac valvular disease; 10046973

• Registration Number: NL-OMON52396
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 400

Inclusion Criteria

- Age > 18 years
- Mild, moderate or Severe degenerative aortic valve stenosis as defined by
transthoracic echocardiography according to the 2017 ESC/EACTS guidelines for
the management of valvular heart disease.

- for the control group:
- 150 healthy subjects without aortic valve stenosis
- 50 subjects with aortic valve stenosis due to congenital biscuspid valve

Exclusion Criteria

For patients and controls:
- Active auto-inflammatory or auto-immune diseases
- Anti-inflammatory drugs
- Vaccination less than one month before inclusion
- Bone marrow transplantation
- Active malignancy, except for local basal cell carcinoma or local squamous
cell skin carcinoma, that can be treated curatively by excision.
- History of endocarditis of the aortic valve
- History of radiation therapy aimed at the chest
- Acute ischemic cardiac event less than three months before inclusion
- Systemic inflammation less than one month before inclusion with fever and/or
for which antibiotics have been prescribed, with the exception for the use of
nitrofurantoin for a urinary tract infection without fever.

Extra exclusion for healthy control subjects:
- History of atherosclerotic cardiovascular events
- Current typical complaints of angina pectoris or intermittent claudication.
- Overt heart failure (NYHA class III/IV)
- Aortic valve stenosis on screenings echocardiography, that will be performed
before inclusion. Mild aortic valve sclerosis is allowed.

Extra exclusion for controls with aortic valve stenosis due to a bicuspid
valve:
- History of atherosclerotic cardiovascular events
- Current typical complaints of angina pectoris or intermittent claudication.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Frequency of CHIP driver mutations in blood cells. </p><br>